how ttx-001 intervenes

TTX-001 is designed to modulate Egr-1 and TGF-β signaling to inactivate fibroblasts, targeting a key driver of excess scar tissue formation.

TTX-001 is designed to inhibit LOX-mediated crosslinking, an approach intended to prevent tissue stiffening and support conditions for fibrosis resolution.

The platform targets fibronectin and collagen deposition pathways, with the goal of reducing extracellular matrix accumulation that characterizes progressive fibrosis.

By targeting MMP and uPA activity, the platform aims to support active breakdown of established fibrotic matrix, addressing a gap not met by currently approved therapies.